We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

097950:KRXCJ Cheiljedang Corporation Analysis

Data as of 2026-03-12 - not real-time

₩201,500.00

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

CJ Cheiljedang trades around the low‑200 k KRW range, well below its DCF‑derived fair value, delivering an apparent upside of more than 30 percent. Technical signals are mixed: the 20‑day and 50‑day SMAs sit just above the current price, RSI hovers in the mid‑40s and the MACD histogram remains negative, suggesting short‑term pressure. Fundamentally, the company shows a very low forward PE of about six and a modest revenue growth of 0.3 percent, while operating margins sit near five percent. However, the balance sheet is heavily leveraged with a debt‑to‑equity ratio above 100 percent and free cash flow is negative, raising concerns about dividend sustainability. The recent earnings call highlighted a 9 percent rise in global food sales, driven by strong performance in the US, Europe and Oceania, which supports the upside narrative. Investor sentiment is very bullish as reflected by an extreme‑greed reading on the fear‑greed index, but the stock’s beta is exceptionally low, indicating limited price volatility relative to the market. Overall, the stock appears undervalued on a valuation basis but carries medium‑term execution risks.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Bearish MACD histogram indicating near‑term downside pressure
  • Current price close to identified support level
  • High dividend payout ratio questioning cash sustainability

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • Significant valuation gap between market price and DCF fair value
  • Stable consumer‑defensive sector with global sales momentum
  • Low beta and stable trading volume reducing market‑price volatility

Long Term

> 3 years
Positive
Model confidence: 6/10

Key Factors

  • Diversified business lines including biotech and specialty solutions
  • Long‑term growth potential from international food and feed markets
  • Management focus on leveraging brand portfolio to improve margins

Key Metrics & Analysis

Financial Health

Revenue Growth0.30%
Profit Margin0.20%
P/E Ratio6.0
ROE1.99%
ROA2.97%
Debt/Equity104.33
Op. Cash Flow₩2234.9B
Free Cash Flow₩-562370772992

Technical Analysis

TrendNeutral
RSI42.9
Support₩186,100.00
Resistance₩235,000.00
MA 20₩211,985.00
MA 50₩211,654.00
MA 200₩228,523.50
MACDBearish
VolumeStable
Fear & Greed Index76.73

Valuation

Fair Value₩701,867.17
Target Price₩268,000.00
Upside/Downside33.00%
GradeUndervalued
TypeValue
Dividend Yield0.75%

Risk Assessment

Beta0.23
Volatility39.00%
Sector RiskLow
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.